Loading
A phase 2 trial of Carboplatin, Pemetrexed in non-small-cell lung cancer and small-cell lung cancer, run by iTeos Therapeutics, active and no longer recruiting.
Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer is a phase 2 interventional study registered as NCT05403385 by iTeos Therapeutics, with 36 participants enrolled, started 2022-08-26 and due to reach its primary completion in 2025-06-13. Interventions recorded: inupadenant, Placebo, Carboplatin, Pemetrexed. Conditions listed: Metastatic NSCLC - Non-Small Cell Lung Cancer, Locally Advanced NSCLC - Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Pemetrexed, Platinum agents, Carboplatin, Small-cell lung cancer.
Shares Pemetrexed, Carboplatin, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Pemetrexed, Platinum agents, Carboplatin, Cytotoxic chemotherapy.
Shares Pemetrexed, Platinum agents, Carboplatin, Cytotoxic chemotherapy.
Shares Pemetrexed, Platinum agents, Carboplatin, Cytotoxic chemotherapy.
Shares Pemetrexed, Platinum agents, Carboplatin, Cytotoxic chemotherapy.
Shares Pemetrexed, Carboplatin, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Pemetrexed, Platinum agents, Carboplatin, Cytotoxic chemotherapy.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/